c-erbB-2激活与卵巢癌预后。与组织学类型、分级及分期的比较。

Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage.

作者信息

Singleton T P, Perrone T, Oakley G, Niehans G A, Carson L, Cha S S, Strickler J G

机构信息

Department of Laboratory Medicine and Pathology, University of Minnesota Hospital and Clinic, Minneapolis.

出版信息

Cancer. 1994 Mar 1;73(5):1460-6. doi: 10.1002/1097-0142(19940301)73:5<1460::aid-cncr2820730523>3.0.co;2-z.

DOI:10.1002/1097-0142(19940301)73:5<1460::aid-cncr2820730523>3.0.co;2-z

PMID:7906608

Abstract

BACKGROUND

Prior reports suggested that measuring c-erbB-2 activation in ovarian carcinomas might be valuable in predicting prognosis. The authors attempted to confirm these studies while specifically excluding tumors of low malignant potential.

METHODS

The clinical and pathologic significance of c-erbB-2 oncogene activation was assessed in 56 ovarian carcinomas, none of which met histologic criteria for tumor of low malignant potential.

RESULTS

By using an immunohistochemical technique previously validated in molecular studies, c-erbB-2 oncogene overexpression was identified in 10 of the 56 carcinomas but did not correlate with histologic type, histologic grade, International Federation of Gynecology and Obstetrics (FIGO) stage, or prognosis. Adverse prognostic factors included histologic type (serous carcinoma), high grade, and high stage (FIGO Stages III and IV). Grade and stage were highly correlated with each other and were more important prognostic indicators than histologic type.

CONCLUSION

Measuring c-erbB-2 activation in ovarian carcinomas may not be of practical value in predicting prognosis when tumors of low malignant potential are excluded.

摘要

背景

先前的报告表明，检测卵巢癌中的c-erbB-2激活情况可能对预测预后有价值。作者试图证实这些研究，同时特别排除低恶性潜能肿瘤。

方法

对56例卵巢癌评估c-erbB-2癌基因激活的临床和病理意义，其中无一例符合低恶性潜能肿瘤的组织学标准。

结果

通过使用先前在分子研究中验证的免疫组织化学技术，在56例癌中有10例发现c-erbB-2癌基因过表达，但与组织学类型、组织学分级、国际妇产科联盟（FIGO）分期或预后均无相关性。不良预后因素包括组织学类型（浆液性癌）、高级别和高分期（FIGO III期和IV期）。分级和分期彼此高度相关，并且是比组织学类型更重要的预后指标。